Clinical trial · Interventional
Prevention of Neuropathic Pain From Oxaliplatin by Photobiomodulation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Peripheral neuropathy is one of the most common side effects of oxaliplatin (OXA)-based chemotherapy for patients treated for digestive cancers, disabling and dose-limiting. Several strategies have been studied for the treatment of oxaliplatin-related sensory neuropathy. Several pharmacological and non-pharmacological therapeutic strategies have been explored to relieve peripheral neuropathic pain. Non-pharmacological interventions have been shown to be potentially beneficial for patients suffering from chemotherapy-induced neurotoxicity. The objective of this prospective study is to evaluate the effectiveness of photobiomodulation on the reduction of neuropathic pain in patients who developed painful, cumulative peripheral neuropathy that appeared under the effect of the treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of the Gastrointestinal Tract | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Photobiomodulation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Control
- description
- Patients will not receive any intervention during their oxaliplatin chemotherapy cycles.
- type
- EXPERIMENTAL
- label
- Experimental
- description
- Patients will receive three photobiomodulation sessions per week during their oxaliplatin chemotherapy cycles
- interventionNames
- Procedure: Photobiomodulation
Primary outcomes (1)
- measure
- Neuropathic Pain Synptom Inventory : pain
- timeFrame
- day 30, day 60, day 90, day 120, day 150, day 180, day 270
- description
- Is is a score with 12 items. 10 items concern pain and are scale from 0 (no pain) to 10 (maximal pain).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Recent diagnosis of digestive cancer * 12 planned cycles of oxaliplatin * Ability to understand and willingness to sign an informed consent form before starting any study procedures * Patient benefiting from French health insurance Exclusion Criteria: * History of neuropathy before the start of the study, * Symptomatic treatment of pain (or neuropathic pain), * Patient with a psychotic disorder, * Patient with diabetic neuropathy, * Patient with metastatic cancer * Patient with renal insufficiency, * Adults under guardianship or curatorship, * Vulnerable people
References
Publications (0)
Data not yet available